Xconomy San Diego — Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday.
The company sold more than 11.9 million shares at $11 apiece. Nearly 1.8 million additional shares are available for its underwriters to purchase.
Synthorx, headed by president and CEO Laura Shawver, had planned to sell 9.1 million shares for between $10 and $12 each. The company’s shares are expected to start trading on the Nasdaq today under the stock symbol “THOR.”